Article History
Received: 20 October 2019
Accepted: 16 January 2020
First Online: 10 February 2020
Compliance with ethical standards
:
: Dr. Arabi is the principal investigator on a clinical trial for lopinavir/ritonavir and interferon in Middle East respiratory syndrome (MERS) and that he was a non-paid consultant on antiviral active for MERS-coronavirus (CoV) for Gilead Sciences and SAB Biotherapeutics. Dr. Hayden’s institution received funding from GlaxoSmithKline (Data Safety Monitoring Board [DSMB] member for influenza randomized-controlled trial [RCT]), Celltrion (DSMB chair for influenza RCT), and Vaccitech (DSMB chair for influenza RCTs); he received honoraria from World Health Organization (consultant on influenza and emerging viral infections) and the University of Alabama (Scientific Advisory Board member for National Institutes of Health-sponsored Antiviral Discovery and Development Consortium); he disclosed that he has been a non-paid consultant on antivirals active for MERS-CoV for Gilead Sciences, SAB Biotherapeutics, and Regeneron, and for multiple companies on influenza therapeutics; Cidara, Shionogi, Seqirus, and resTORbio have made charitable contributions to the Ford Haitian Orphanage and School for his consulting time; Shionogi and Roche have provided meeting travel support.
Free to read: This content has been made available to all.